Skip to main content

Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.

Publication ,  Journal Article
Kinsey, EN; Zhang, T; Armstrong, AJ
Published in: Cancer J
2020

PURPOSE: In recent years, the treatment options for metastatic hormone-sensitive prostate cancer (mHSPC) have expanded significantly. In addition to androgen deprivation therapy, the systemic treatments now include docetaxel, abiraterone, enzalutamide, and apalutamide. Radiation to the primary is also an option for select low-volume patients. METHODS: We conducted a review of the pivotal trials that have changed the practice of mHSPC. RESULTS: We describe an overview of the trials that investigated docetaxel (CHAARTED and STAMPEDE-Docetaxel), abiraterone (LATTITUDE and STAMPEDE-Abiraterone), enzalutamide (ARCHES, ENZAMET), apalutamide (TITAN), and radiation to the primary (STAMPEDE-Radiation). DISCUSSION: The treatment of mHSPC is a complex topic, and treatment choice should be individualized. Patient preferences, cost, volume of disease, and side effect profiles are important in determining which option is the best for an individual patient.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer J

DOI

EISSN

1540-336X

Publication Date

2020

Volume

26

Issue

1

Start / End Page

64 / 75

Location

United States

Related Subject Headings

  • Time Factors
  • Thiohydantoins
  • Randomized Controlled Trials as Topic
  • Prostatic Neoplasms
  • Phenylthiohydantoin
  • Oncology & Carcinogenesis
  • Nitriles
  • Medical Oncology
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kinsey, E. N., Zhang, T., & Armstrong, A. J. (2020). Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape. Cancer J, 26(1), 64–75. https://doi.org/10.1097/PPO.0000000000000418
Kinsey, Emily N., Tian Zhang, and Andrew J. Armstrong. “Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.Cancer J 26, no. 1 (2020): 64–75. https://doi.org/10.1097/PPO.0000000000000418.
Kinsey EN, Zhang T, Armstrong AJ. Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape. Cancer J. 2020;26(1):64–75.
Kinsey, Emily N., et al. “Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.Cancer J, vol. 26, no. 1, 2020, pp. 64–75. Pubmed, doi:10.1097/PPO.0000000000000418.
Kinsey EN, Zhang T, Armstrong AJ. Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape. Cancer J. 2020;26(1):64–75.

Published In

Cancer J

DOI

EISSN

1540-336X

Publication Date

2020

Volume

26

Issue

1

Start / End Page

64 / 75

Location

United States

Related Subject Headings

  • Time Factors
  • Thiohydantoins
  • Randomized Controlled Trials as Topic
  • Prostatic Neoplasms
  • Phenylthiohydantoin
  • Oncology & Carcinogenesis
  • Nitriles
  • Medical Oncology
  • Male
  • Humans